Introduction
ALA (alpha-lipoic acid, also called thioctic acid) is a naturally occurring organosulfur compound and mitochondrial cofactor found in the body and in foods, with human research focused most strongly on diabetic peripheral neuropathy, type 2 diabetes-related metabolic outcomes, obesity and weight regulation, and smaller neurological studies such as multiple sclerosis and burning mouth syndrome (Research) (Review).
ALA is studied in humans mainly as an administered oral compound rather than as a dietary exposure, and the most developed clinical literature concerns diabetic neuropathy and related metabolic settings (Review) (Research). Human evidence also includes obesity-focused randomized trials and meta-analyses, while findings in burning mouth syndrome and multiple sclerosis are smaller and more mixed or exploratory (Review) (Review). Overall, the evidence base is usable but incomplete: there are multiple human trials, but formulation differences, heterogeneous outcomes, and limited pharmacokinetic characterization constrain confidence (Review) (Research).
Ingredient Snapshot
- Entity: ALA (Alpha-Lipoic Acid)
- Chemical or biological class: Organosulfur compound; mitochondrial redox cofactor (Research)
- Endogenous vs exogenous: Both; it is produced in the body and also administered as an oral compound in human studies (Research)
- Primary human research domains: Diabetes and Glycemic Control; Neurological Health; Obesity and Weight Regulation (Review) (Review) (Review)
- Common study formats: Randomized placebo-controlled oral trials, adjunctive neuropathy studies, and meta-analyses of heterogeneous oral regimens (Research) (Review)
- Pharmacokinetic characterization status: Limited in the cited source set; a human PK study is available mainly from a fixed-dose combination context rather than a broad standalone ALA PK literature (Research)
- Regulatory context (U.S./EU): In the U.S., the cited FDA materials provide dietary-supplement framework context and a food-use GRAS notice context rather than drug approval or efficacy evaluation (FDA) (FDA). In the EU, the cited EFSA opinion addresses insulin autoimmune syndrome risk associated with ALA rather than broad authorization status (EFSA).
Research Snapshot
ALA is best characterized in human research as an orally administered redox-active compound studied most extensively in diabetic peripheral neuropathy and more broadly in type 2 diabetes-related metabolic settings. Secondary human research areas include obesity and weight regulation, while the evidence for multiple sclerosis and burning mouth syndrome is smaller and less consistent (Review) (Review) (Review).
Typical studied oral exposures in the cited human literature range from 300 mg/day to 1,800 mg/day, with many trials clustering around 600 mg/day and some metabolic or neurological studies using 1,200 mg/day or 600 mg twice daily (Research) (Research) (Research). The main interpretive limitations are that outcomes vary by condition, some studies are adjunctive rather than standalone, and pharmacokinetic evidence in the cited source set is limited and formulation-sensitive (Research) (Research). Overall, the human evidence is broader than a niche pilot literature but not mature enough to treat all studied domains as equally established (Review).
Introduction
Alpha-lipoic acid is a sulfur-containing compound that functions as a cofactor in mitochondrial energy metabolism, meaning it helps certain enzyme systems process energy inside cells (Research). It is present endogenously and is also available as an administered oral compound used in clinical research across metabolic and neurological settings (Research).
People usually look up ALA because it appears in discussions of diabetic neuropathy, blood sugar-related metabolism, body weight, and oxidative-stress-related neurological research (Review) (Review). Human studies have examined it in both standalone and adjunctive designs, which helps explain why the literature includes both positive and neutral findings across different conditions and formulations (Research) (Research).
This article is informational only, describes ALA as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- ALA is a naturally occurring organosulfur compound and mitochondrial cofactor that has been studied in humans mainly as an oral administered compound rather than as a food-intake exposure (Research) (Research).
- The strongest human research area is diabetic peripheral neuropathy, where randomized trials and reviews report symptom-focused outcomes, although not all neuropathy studies are uniformly favorable (Research) (Review).
- In type 2 diabetes metabolic research, findings are mixed: some trials report changes in glucose-related physiology, while others do not show clear improvement in inflammatory or metabolic endpoints (Research) (Research) (Research).
- In obesity and weight regulation, randomized trials and meta-analyses suggest small short-term reductions in body weight or BMI, but the effect sizes are modest and study regimens are heterogeneous (Research) (Review).
- Evidence in burning mouth syndrome is mixed, with one placebo-controlled trial reporting benefit and another reporting no clear efficacy (Research) (Research) (Review).
- Short-term human research in multiple sclerosis has focused more on biomarkers and exploratory disability-related measures than on definitive long-term clinical outcomes (Research) (Research).
- Safety signals in the cited sources include generally mild short-term trial tolerability, dose-related adverse effects in some neuropathy studies, and an EFSA-reviewed risk of insulin autoimmune syndrome in susceptible individuals (Research) (EFSA).
Human Research Findings by Condition
Diabetes and Glycemic Control
Human research on diabetes-related uses of ALA is strongest in diabetic peripheral neuropathy and more mixed for broader metabolic endpoints in type 2 diabetes. The evidence includes randomized oral trials, adjunctive neuropathy studies, and meta-analyses with heterogeneous endpoints (Review) (Review).
Dose studied: 600, 1,200, or 1,800 mg/day
Population: Adults with symptomatic diabetic polyneuropathy
Duration: 5 weeks
Researchers compared three once-daily oral dose levels of ALA against placebo in symptomatic diabetic polyneuropathy. Positive sensory symptoms improved across active-treatment groups, and the 600 mg/day group showed the most favorable tolerability profile among the tested regimens.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
(Review)
Dose studied: 600 mg twice daily
Population: Lean and obese patients with type 2 diabetes
Duration: 4 weeks
This randomized study examined oral ALA in type 2 diabetes with metabolic endpoints rather than neuropathy symptoms. The trial reported improved glucose effectiveness and lower lactate and pyruvate concentrations, with clearer insulin-sensitivity improvement in lean participants than in obese participants. This result applies only within the conditions of the cited study.
Result: Human clinical study reported a modest improvement
Evidence strength: Moderate
Study source: (Research)
(Review)
Neurological Health
Neurological research on ALA is split between diabetic neuropathy-adjacent pain studies and smaller exploratory work in multiple sclerosis. Results are not uniform across these settings, and some studies are biomarker-focused or comparator-driven rather than clear efficacy demonstrations (Research) (Research).
Dose studied: 1,200 mg/day
Population: Adults with relapsing-remitting multiple sclerosis
Duration: 12 weeks
This randomized trial evaluated oral ALA in relapsing-remitting multiple sclerosis and measured asymmetric dimethylarginine (ADMA), a vascular and inflammatory biomarker, alongside disability-related outcomes. The study reported reduced ADMA and a favorable short-term signal in disability-related measures, but the sample was small and the trial was exploratory. This evidence does not establish long-term or general-population effects.
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Dose studied: Oral ALA; exact standalone regimen not clearly extractable from the cited summary here
Population: Patients with mixed neuropathic pain populations in the PAIN-CARE trial
Duration: Crossover trial duration not clearly extractable here from the cited summary set
The PAIN-CARE crossover trial compared ALA with pregabalin and with combination therapy in neuropathic pain populations. In that trial, ALA was inferior to pregabalin for pain intensity, and combination therapy did not show added benefit over pregabalin alone. This finding is limited to the study population and duration.
Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)
Obesity and Weight Regulation
Human studies on ALA and body weight suggest a modest signal rather than a large or uniform effect. The evidence includes randomized trials and meta-analyses, but the underlying regimens, populations, and co-interventions are heterogeneous (Review) (Review).
Dose studied: 600 mg/day
Population: Overweight or obese adults with elevated triglycerides
Duration: 24 weeks
This randomized placebo-controlled trial tested oral R-ALA in adults with overweight or obesity and elevated triglycerides. The study reported greater BMI reduction in the active-treatment group than in placebo over 24 weeks. This result applies only within the conditions of the cited study.
Result: Human clinical study reported a modest improvement
Evidence strength: Moderate
Study source: (Research)
(Review)
Dose studied: 300 mg/day
Population: Overweight and obese women under calorie restriction
Duration: Trial duration not clearly extractable from the cited summary beyond diet-intervention context
This trial examined ALA within an energy-restriction program rather than as an isolated free-living weight-loss intervention. Weight loss improved relative to control, but one arm also involved EPA, so the result should be read as diet-context and partly combination-context evidence rather than a universal monotherapy finding. The findings are specific to the study design and may not generalize beyond it.
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Oral Health
The main oral-health research area for ALA in the cited sources is burning mouth syndrome. Human evidence is mixed, with both positive and neutral placebo-controlled trials and a review describing overall trial-quality limitations (Research) (Research) (Review).
Dose studied: Oral ALA; commonly 600-800 mg/day across reviewed trials
Population: Adults with burning mouth syndrome
Duration: 2 months in the cited placebo-controlled trial
A double-blind controlled trial reported symptomatic improvement in burning mouth syndrome with oral ALA compared with placebo over two months. Because later evidence was not consistently positive, this trial is best interpreted as one positive study within a mixed overall domain.
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
(Review)
Dose studied: Oral ALA; exact regimen not clearly extracted here beyond placebo-controlled oral use
Population: Adults with burning mouth syndrome
Duration: Trial duration not clearly extractable here from the cited summary set
Another randomized placebo-controlled trial did not show clear efficacy for burning mouth syndrome. This conflicting result is one reason the overall oral-health literature remains mixed rather than consistently favorable.
Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)
(Review)
Dosage & Study Snapshot (Research Context)
Human ALA exposure in the cited literature is mainly from oral intervention trials rather than dietary intake studies. The evidence clusters around 300 mg/day, 600 mg/day, 1,200 mg/day, and 1,800 mg/day, with several neuropathy and diabetes studies using 600 mg/day or 600 mg twice daily, and one chemotherapy-prevention trial using 600 mg three times daily (Research) (Research) (Research). The lowest documented exposure in the cited human trials is a weight-loss diet-intervention context rather than the main neuropathy-focused literature, so the first band should not be mistaken for the dominant research anchor.
This is the lowest documented oral daily exposure in the cited human intervention set. It appears in a calorie-restriction trial in overweight and obese women, where ALA was used within a diet program rather than as a pure standalone metabolic therapy. The study reported greater weight loss relative to control, but the context matters because one arm also involved EPA and the intervention was diet-structured. This makes the evidence more context-specific than the neuropathy literature. For readers comparing research settings, this band reflects a lower-dose weight-management context rather than the core diabetes-neuropathy evidence base (Research).
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: This is diet-context evidence and may not generalize to standalone ALA use.
This is the most common oral daily exposure across several cited studies and appears in diabetic neuropathy, obesity, type 2 diabetes, and adjunctive neuropathy trials. In symptomatic diabetic polyneuropathy, 600 mg/day improved positive sensory symptoms over 5 weeks and showed a more favorable tolerability profile than higher tested doses in that study. Other 600 mg/day studies reported greater BMI reduction with R-ALA over 24 weeks in adults with elevated triglycerides, while some diabetes biomarker studies found no clear advantage over placebo for inflammatory or oxidative-stress endpoints. In adjunctive diabetic neuropathy settings, 600 mg/day was also used with gabapentin or pregabalin over 12 weeks, adding context but not always clean monotherapy interpretation. Overall, this band is the main practical anchor of the human intervention literature (Research) (Research).
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Findings vary by population, outcome, and whether ALA was studied alone or as adjunctive therapy.
This repeated-dose regimen was studied in lean and obese patients with type 2 diabetes over 4 weeks. Researchers assessed glucose effectiveness and related metabolic markers rather than neuropathic symptoms or body weight. The trial reported improved glucose effectiveness and lower lactate and pyruvate concentrations, with clearer insulin-sensitivity improvement in lean participants than in obese participants. This makes the band relevant mainly for short-term metabolic physiology, not for the broader neuropathy-focused evidence base (Research).
Result: Modest improvement
Evidence strength: Moderate
Notes / limitations: This was a short metabolic study and does not establish long-term diabetes outcomes.
This exposure appears in both diabetic polyneuropathy and multiple sclerosis research. In the neuropathy dose-comparison trial, 1,200 mg/day improved symptoms but was associated with more adverse effects than 600 mg/day, which limited its practical advantage in that trial. In relapsing-remitting multiple sclerosis, 1,200 mg/day for 12 weeks was used in a small exploratory trial focused on ADMA and short-term disability-related measures. This band therefore includes both efficacy-oriented neuropathy data and exploratory neurological biomarker work rather than one uniform evidence stream (Research) (Research).
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Evidence at this dose is condition-specific and not consistently supported across outcomes.
This higher once-daily exposure is documented in the diabetic polyneuropathy dose-ranging trial. Symptom improvement was reported, but adverse effects were more frequent than at lower doses, and the study did not establish a clearer practical advantage over 600 mg/day. The available cited evidence for this band is therefore tied mainly to one short neuropathy study rather than to a broad literature across conditions (Research).
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: The evidence at this dose comes mainly from one 5-week neuropathy trial.
This is the highest documented repeated daily oral exposure in the cited human trials. It was used in a 24-week placebo-controlled prevention study in adults receiving platinum-based chemotherapy, where the goal was to reduce chemotherapy-induced peripheral neuropathy. The trial did not show significant benefit versus placebo, and completion was poor, which also limits interpretability. This high-dose context is therefore a narrow prevention setting rather than a general-use anchor for ALA (Research).
Result: No clear effect
Evidence strength: Limited
Notes / limitations: This regimen comes from a prevention trial with high attrition in a non-core clinical context.
Key Takeaways from Human Research
- The most developed human evidence for ALA is in diabetic peripheral neuropathy, where randomized trials and reviews support symptom-focused research interest, although not all neuropathy trials are favorable in comparator settings (Research) (Research) (Review).
- In type 2 diabetes metabolic research, some studies report improvements in glucose-related physiology, but other trials and meta-analyses show heterogeneous or neutral results across inflammatory and glycemic markers (Research) (Research) (Review).
- In obesity and weight regulation, the human signal is generally modest, with meta-analyses describing small short-term reductions in body weight or BMI rather than large effects (Research) (Review).
- Evidence in burning mouth syndrome remains mixed because placebo-controlled trials do not point in the same direction, and review-level assessments note trial-quality limitations (Research) (Research) (Review).
- Short-term multiple sclerosis studies are exploratory and biomarker-oriented, so they do not establish broad clinical efficacy (Research) (Research).
- Across the cited literature, interpretation is limited by formulation differences, adjunctive trial designs, heterogeneous endpoints, and relatively thin standalone pharmacokinetic coverage (Research) (Research) (Review).
Ingredient Identity
- Official name(s): Alpha-lipoic acid; thioctic acid
- Synonyms: ALA; α-lipoic acid
- Classification: Organosulfur redox-active compound; mitochondrial cofactor
- CAS number (if available): Not clearly provided in the cited source set
- Endogenous vs exogenous (if applicable): Both endogenous and exogenously administered in human studies
Origin & Natural Occurrence
ALA is an endogenous compound involved in mitochondrial enzyme systems, meaning the body uses it in energy-related biochemical reactions (Research). In research and commercial contexts, it is also administered orally as alpha-lipoic acid or R-alpha-lipoic acid, which is why most human evidence in this article concerns direct-use oral exposure rather than food-intake measurement (Research) (Research).
The cited FDA GRAS notice adds food-use context by describing alpha-lipoic acid for specified dry-food uses for adults, but that document is a food-use notice rather than a drug evaluation (FDA). In practice, the cited literature here is dominated by administered-study formulations rather than natural-food exposure studies (Research).
How It Behaves in the Body
ALA is studied as a compound involved in cellular energy metabolism and redox balance, meaning it participates in reactions related to energy production and the handling of oxidant stress (Research). In plain terms, researchers are interested in it because it may influence how cells process fuel, how oxidative stress markers behave, and how some nerve-related symptoms or metabolic signals change in clinical settings (Review) (Review).
In type 2 diabetes studies, ALA has been examined for effects on glucose effectiveness, insulin sensitivity, and related metabolites such as lactate and pyruvate (Research). In multiple sclerosis and other biomarker-focused work, researchers have also measured markers linked to oxidative stress or endothelial biology, such as ADMA, to see whether ALA changes short-term physiology (Research) (Research). In diabetic hemodialysis patients, trials have additionally tracked inflammatory and oxidative-stress markers together with anemia-related measures (Research).
What is well established from the cited sources is that ALA can be administered orally and can change some measured physiological markers in humans. What is less established is how consistently those short-term biochemical or symptom changes translate across conditions, formulations, and longer-term clinical outcomes (Review) (Review).
Absorption & Delivery Formats
Oral immediate-release is the main delivery format represented in the cited human trials, including once-daily, twice-daily, and three-times-daily regimens across neuropathy, metabolic, obesity, and neurological studies (Research) (Research) (Research). The source set also includes R-ALA as a specific oral formulation in one obesity study, which suggests that formulation identity can matter when comparing results across trials (Research).
Evidence for oral extended-release is not clearly established in the cited source set. Evidence for sublingual and transdermal delivery is also not present in the cited sources reviewed for this article.
For injectable / IV use, the cited source library does not provide a core human trial set sufficient to characterize it here, so this article remains centered on oral exposure. Pharmacokinetic detail is limited overall, and the available human PK citation comes mainly from a fixed-dose combination study with pregabalin and thioctic acid in healthy volunteers (Research).
Quick Facts at a Glance
Onset (reported)
Reported onset depends on the outcome being measured. In diabetic neuropathy, symptom-focused changes were reported over 5 weeks in the SYDNEY 2 study, while some metabolic studies examined shorter 4- to 6-week intervals and obesity trials extended to 24 weeks (Research) (Research) (Research). This means the cited human evidence is oriented more toward short- to medium-duration trial outcomes than toward immediate subjective onset.
Time to peak (Tmax)
The cited source set does not provide a robust standalone Tmax characterization for isolated oral ALA. The available pharmacokinetic evidence is mainly from a fixed-dose combination study in healthy volunteers, which is useful for interaction context but does not provide a broad standalone Tmax framework for all ALA formulations (Research). Researchers therefore have some PK context in the cited literature, but not enough here for a comprehensive formulation-by-formulation Tmax summary.
Half-life (t½)
A clear standalone ALA half-life summary is not established in the cited source set. The PK evidence available here is limited and combination-based, so it supports only cautious statements about incomplete pharmacokinetic characterization rather than a definitive t½ reference value (Research). For this reason, the article does not present a single universal half-life figure.
Typical duration
Most cited oral human studies lasted from 4 to 12 weeks, although some extended to 24 weeks and one hemodialysis study ran for 6 months (Research) (Research) (Research) (Research). This indicates that the clinical literature is stronger for short- and intermediate-duration exposure than for long-term use patterns.
Absorption routes studied
The cited human literature is dominated by oral administration. No comparable evidence base for sublingual, transdermal, or injectable delivery appears in the cited source set used for this article (Research) (Research).
Formulation differences
Formulation differences are relevant because the source set includes standard oral ALA, oral R-ALA, adjunctive use with neuropathic-pain drugs, and a fixed-dose PK combination with pregabalin and thioctic acid (Research) (Research) (Research). These differences complicate direct comparison across outcomes and make it harder to assume all findings apply equally to all product forms.
Variability drivers
Variability in results appears to be driven by condition studied, dose, formulation, co-interventions, and whether the study was standalone or adjunctive (Review) (Review). Some studies also suggest differences by population characteristics, such as lean versus obese participants in type 2 diabetes research (Research).
Tolerance / adaptation
The cited source set does not establish a clear tolerance or adaptation pattern in the classic sense. What it does show is that higher oral doses in one neuropathy trial were associated with more adverse effects, while short-term tolerability at 600 mg/day was generally acceptable in several study settings (Research) (Research). This is better described as dose-related tolerability variation than as confirmed physiological tolerance.
Evidence strength snapshot
The human evidence is strongest for diabetic peripheral neuropathy, moderate-to-limited for obesity and type 2 diabetes metabolic outcomes, and emerging or mixed for multiple sclerosis and burning mouth syndrome (Review) (Review) (Review). Confidence is not higher because the literature is heterogeneous, formulation-sensitive, and not equally mature across all studied domains (Review).
Other Physiological Contexts Studied
- In chemotherapy-related neuropathy prevention, oral ALA 600 mg three times daily did not reduce platinum-related neurotoxicity versus placebo, and trial completion was poor, limiting interpretation (Research).
- In diabetic hemodialysis patients, oral ALA 600 mg/day was studied alongside standard care and was associated with lower inflammatory and oxidative-stress markers and changes in anemia-related measures, but this remains a context-specific population (Research).
- In adjunctive neuropathy studies, ALA has been tested together with gabapentin or pregabalin, which makes those findings useful but less clean for judging ALA as isolated monotherapy (Research) (Research).
- In the cited PK interaction literature, co-administration with pregabalin in healthy volunteers did not show a clinically meaningful pharmacokinetic interaction, which is relevant to delivery-context interpretation rather than efficacy (Research).
Safety, Interactions & Regulation
Short-term clinical studies in the cited literature generally describe ALA as having relatively mild adverse effects, but tolerability is dose-sensitive in some settings (Research) (Research). In SYDNEY 2, higher oral doses were associated with more adverse effects than 600 mg/day, which is why tolerability interpretation should be separated from efficacy interpretation (Research). LiverTox states that clinically apparent liver injury from alpha-lipoic acid appears very rare in the available literature reviewed there (Research).
A notable safety signal in the cited regulatory literature concerns insulin autoimmune syndrome. EFSA concluded that a cause-and-effect relationship exists between consumption of alpha-lipoic acid and insulin autoimmune syndrome in susceptible individuals (EFSA). This does not mean the event is common, but it is a documented authority-reviewed risk in a defined susceptible group based on the cited source (EFSA).
Interaction-wise, the cited human PK study found no clinically meaningful pharmacokinetic interaction in a fixed-dose combination of pregabalin and thioctic acid in healthy volunteers, but that finding is limited to the studied combination context and does not establish a universal interaction profile (Research). Adjunctive diabetic neuropathy studies also show that ALA has been co-administered with gabapentin or pregabalin in clinical settings, which is useful context but not a comprehensive interaction map (Research) (Research).
In the U.S., the cited FDA dietary supplement compliance material provides general framework context for products marketed under the dietary supplement framework rather than ingredient-specific approval (FDA). The cited FDA GRAS notice provides food-use context for alpha-lipoic acid in dry foods for adults and does not constitute drug approval or efficacy evaluation (FDA). In the EU, the cited EFSA document provides safety-risk context regarding insulin autoimmune syndrome and should not be read as a broad authorization statement for all ALA product uses (EFSA).
Evidence Overview
Human evidence for ALA is strongest in diabetic peripheral neuropathy, more mixed in type 2 diabetes metabolic outcomes and burning mouth syndrome, and more limited or exploratory in multiple sclerosis and narrower contexts such as chemotherapy-related neuropathy prevention (Review) (Review) (Review). The literature is dominated by randomized oral intervention trials and meta-analyses of heterogeneous regimens, while standalone pharmacokinetic characterization remains relatively thin in the cited source set (Research) (Review) (Research). Confidence is not higher because results vary by condition, formulation, comparator, and whether ALA was used as monotherapy or as an adjunct (Research) (Research).
Randomized human trial evidence is most representative in diabetic neuropathy. The SYDNEY 2 trial supports a symptom-focused signal across several oral dose levels, while newer adjunctive studies add clinical context but are not clean monotherapy efficacy trials (Research) (Research) (Research). At the same time, not every neuropathy-focused study is favorable: the PAIN-CARE trial found ALA inferior to pregabalin, and a chemotherapy-prevention trial found no benefit for prevention of platinum-related neuropathy (Research) (Research). This contrast shows that neuropathy-related findings are not interchangeable across disease settings or study designs.
For type 2 diabetes and metabolic outcomes, the evidence is mixed and endpoint-dependent. Some trials report improved glucose effectiveness or shifts in biochemical markers, while others show no clear advantage for oxidative-stress, inflammatory, or metabolic endpoints over placebo (Research) (Research) (Research). Meta-analyses also describe heterogeneity across HbA1c, fasting glucose, CRP, triglycerides, and related measures, which means the metabolic literature is broader than the evidence for one single clinically consistent effect (Review) (Review).
For obesity and weight regulation, randomized trials and meta-analyses point to small average reductions in weight or BMI rather than large changes (Research) (Review) (Review). For burning mouth syndrome, evidence remains mixed because some placebo-controlled trials report symptom improvement and others do not, and review-level assessments note trial-quality limitations (Research) (Research) (Review). Multiple sclerosis research is narrower and supported mainly by small biomarker-oriented trials rather than definitive long-term clinical studies (Research) (Research).
What would strengthen confidence is a more standardized clinical literature with clearer formulation reporting, more standalone PK data, larger longer-duration randomized trials, and more consistent endpoint selection within each condition area (Research) (Review).
Evidence Confidence Classification
The overall human evidence for ALA is Limited / Mixed, based on multiple human studies with the strongest support in diabetic peripheral neuropathy but important limitations in consistency, formulation comparability, and domain-to-domain maturity (Review) (Review).
Interventional human evidence is present across neuropathy, type 2 diabetes, obesity, burning mouth syndrome, and multiple sclerosis, but the signal is not equally consistent across those domains (Research) (Research) (Research). Observational and synthesis evidence broadens the picture for weight, lipids, and biomarker outcomes, while mechanistic and short-term physiological studies help explain interest in ALA without establishing uniform clinical effects (Review) (Review). Regulatory context in the cited sources is framework-level in the U.S. and safety-risk-focused in the EU, rather than evidence of broad ingredient-specific approval for clinical use (FDA) (EFSA).
Similar Ingredients & Comparators
Similar ingredients or related compounds:
- R-alpha-lipoic acid
- Thioctic acid
- Acetyl-L-carnitine
- Coenzyme Q10
- N-acetylcysteine
- Benfotiamine
- Pyridoxine
- Methylcobalamin
- Omega-3 fatty acids
- Vitamin E
- Carnitine
- Glutathione-related compounds
Medical / pharma comparator categories:
- Neuropathic pain agents
- Anticonvulsant pain modulators
- Glucose-lowering therapies
- Weight-management pharmacotherapies
- Antioxidant pharmacology comparators
Combination Context
ALA + Pregabalin:
This combination has been studied both in neuropathic-pain efficacy research and in pharmacokinetic interaction work. In the PAIN-CARE trial, combination therapy did not outperform pregabalin alone for pain intensity, while a separate PK study in healthy volunteers did not show a clinically meaningful pharmacokinetic interaction in the studied fixed-dose combination (Research) (Research).
ALA + Gabapentin:
ALA has been studied as an adjunct in diabetic neuropathy populations already receiving gabapentin or pregabalin. These studies add useful clinical context, but they are not clean standalone ALA monotherapy trials, so attribution of effects should remain cautious (Research) (Research).
ALA + EPA:
One weight-loss trial in overweight and obese women included an arm combining ALA with EPA within an energy-restriction program. That makes the finding useful for combination-context interpretation, but it also means the result should not be generalized as isolated ALA evidence without qualification (Research).
FAQ
What is this ingredient½
ALA is alpha-lipoic acid, also called thioctic acid, a naturally occurring organosulfur compound that functions as a mitochondrial cofactor in energy metabolism (Research). It is present in the body and has also been studied as an administered oral compound in clinical research (Research). In the cited human literature, it is studied mainly in diabetic neuropathy, type 2 diabetes-related metabolic outcomes, obesity and weight regulation, and smaller neurological or oral-health settings (Review) (Review).
What does human research study it for?
Human research studies ALA most often for diabetic peripheral neuropathy and for metabolic questions related to type 2 diabetes (Review) (Review). Additional human research has examined obesity and weight regulation, burning mouth syndrome, and multiple sclerosis, although these areas are either more mixed or less mature (Review) (Review) (Research). Some studies also focus on biomarkers or adjunctive use rather than direct clinical efficacy endpoints (Research).
What are the best-supported uses?
The best-supported human research area is diabetic peripheral neuropathy (Research) (Review). That conclusion is based on randomized trials and review-level evidence showing recurring study attention and symptom-focused outcomes in that domain (Research) (Review). Even there, not every neuropathy study is positive across all designs, so “best-supported” does not mean uniformly confirmed across every neuropathic context (Research).
Where is evidence mixed or limited?
Evidence is mixed in type 2 diabetes metabolic endpoints, obesity and weight regulation, and burning mouth syndrome (Research) (Review) (Review). Some studies report favorable changes, but others report neutral findings or rely on smaller, more heterogeneous trial sets (Research) (Research). Evidence in multiple sclerosis is narrower and remains exploratory, with short-term biomarker-focused trials rather than a large long-term efficacy literature (Research) (Research).
How quickly does it act (onset)?
The cited human literature does not establish one universal onset time for ALA across all uses (Research) (Research). Reported study durations linked to observed changes range from about 4 to 6 weeks in some diabetes-related trials to 12 weeks in multiple sclerosis and 24 weeks in some obesity or prevention studies (Research) (Research) (Research). That means onset depends on the outcome being measured and the clinical context studied rather than following one single timeline (Review).
What affects absorption and variability?
Absorption and variability are affected in the cited literature mainly by formulation, dose, population, and whether ALA is studied alone or alongside other agents (Research) (Research). The source set includes standard ALA, R-ALA, and fixed-dose combination exposure, which makes direct comparison across trials less straightforward (Research). Variability is also driven by condition-specific study design and outcome choice, which helps explain why some domains look more favorable than others (Review) (Review).
Is tolerance reported?
A clear physiological tolerance pattern is not established in the cited source set (Research). What the cited studies do show is dose-related tolerability variation, with higher doses in SYDNEY 2 associated with more adverse effects than 600 mg/day (Research). Short-term trials at 600 mg/day also reported acceptable tolerability in some diabetic neuropathy settings, including no serious adverse events in one 12-week adjunctive study (Research).
Why do studies disagree?
Studies disagree mainly because they examine different conditions, different doses, different formulations, and different trial designs (Review) (Review). Some studies are standalone efficacy trials, while others are adjunctive, biomarker-focused, or combination-based, which changes how directly the results can be interpreted (Research) (Research). The literature is therefore broader than a single uniform clinical effect model (Review).
What ingredients is it commonly combined with and why?
In the cited human literature, ALA is commonly combined with pregabalin, gabapentin, or EPA in specific research settings (Research) (Research). Pregabalin and gabapentin combinations appear mainly in neuropathic-pain or adjunctive diabetic neuropathy contexts, while EPA appeared in a calorie-restriction weight-loss study (Research) (Research). These combinations are useful for understanding the literature, but they do not all represent clean evidence about isolated ALA alone (Research).
What foods naturally contain this ingredient½
The cited source set supports ALA as an endogenous compound and includes FDA food-use context, but it does not provide a detailed food-composition literature set for ranking natural food sources (Research) (FDA). For that reason, this article can say that ALA has food-use context and biological natural occurrence, but it does not provide a quantified food-source table. The main human evidence reviewed here is based on administered oral-study exposure rather than dietary intake tracking (Research).
How is it regulated?
In the U.S., the cited FDA sources provide framework-level context rather than ingredient-specific drug approval (FDA). The cited FDA GRAS source provides food-use context for alpha-lipoic acid in dry foods for adults and does not constitute drug approval or efficacy evaluation (FDA). In the EU, the cited EFSA opinion addresses safety risk, specifically insulin autoimmune syndrome in susceptible individuals, within that regulatory context rather than serving as a broad authorization statement (EFSA).
Resources
- SYDNEY 2 diabetic polyneuropathy trial – PubMed – https://pubmed.ncbi.nlm.nih.gov/17065669/
- Type 2 diabetes metabolic trial – PubMed – https://pubmed.ncbi.nlm.nih.gov/10333946/
- Obesity trial with R-ALA – PubMed – https://pubmed.ncbi.nlm.nih.gov/32692358/
- Obesity meta-analysis – PubMed – https://pubmed.ncbi.nlm.nih.gov/28295905/
- Type 2 diabetes dose-response meta-analysis – PubMed – https://pubmed.ncbi.nlm.nih.gov/36006850/
- Diabetic polyneuropathy systematic review/meta-analysis – PubMed – https://pubmed.ncbi.nlm.nih.gov/41619689/
- Burning mouth syndrome systematic review – PubMed – https://pubmed.ncbi.nlm.nih.gov/36246031/
- PK interaction study with pregabalin/thioctic acid – PubMed – https://pubmed.ncbi.nlm.nih.gov/41079751/
- LiverTox alpha-lipoic acid monograph – NCBI Bookshelf – https://www.ncbi.nlm.nih.gov/books/NBK591554/
- FDA dietary supplement compliance framework – FDA – https://www.fda.gov/files/food/published/CP7321.008-DietarySupplements-09182024.pdf
- FDA GRAS notice for alpha-lipoic acid food use – FDA – https://www.fda.gov/media/165474/download
- EFSA opinion on insulin autoimmune syndrome risk – EFSA – https://www.efsa.europa.eu/en/efsajournal/pub/6577
